New pathways to control inflammatory responses in adipose tissue

Area of Science:

• * Immunology and metabolic disease research.
• * Pharmacological targeting of inflammatory pathways.

Background:

• * Obesity is associated with chronic adipose tissue inflammation, particularly visceral fat.
• * This inflammation is a key factor in obesity-associated comorbidities and insulin resistance.
• * Current research focuses on understanding these inflammatory mechanisms for therapeutic intervention.

Purpose of the Study:

• * To review recent evidence on pharmacological targets for adipose tissue inflammation.
• * To identify mediators studied in chronic inflammatory diseases as potential obesity therapies.
• * To explore novel agonist therapies for inflammation resolution.

Main Methods:

• * Literature review of recent scientific evidence.
• * Focus on inflammasomes, T regulatory cells, and inflammation resolution mediators.
• * Analysis of potential therapeutic candidates for obesity-associated inflammation.

Main Results:

• * The inflammasome pathway and its products are identified as a key target for anti-inflammatory strategies.
• * T regulatory (Treg) cells show potential in modulating adipose tissue inflammation.
• * Mediators of inflammation resolution, including resolvins, protectins, annexin A1 (ANXA1), and galectins, are promising targets for novel therapies.

Conclusions:

• * Targeting adipose tissue inflammation offers a promising therapeutic avenue for obesity and its comorbidities.
• * Inhibiting inflammasomes and activating Treg cells are viable anti-inflammatory strategies.
• * Novel agonist therapies targeting inflammation resolution mediators present new opportunities for treatment.